| Literature DB >> 35840765 |
Minzhang Zheng1,2, Carlo Piermarocchi3, George I Mias4,5,6.
Abstract
Longitudinal deep multiomics profiling, which combines biomolecular, physiological, environmental and clinical measures data, shows great promise for precision health. However, integrating and understanding the complexity of such data remains a big challenge. Here we utilize an individual-focused bottom-up approach aimed at first assessing single individuals' multiomics time series, and using the individual-level responses to assess multi-individual grouping based directly on similarity of their longitudinal deep multiomics profiles. We used this individual-focused approach to analyze profiles from a study profiling longitudinal responses in type 2 diabetes mellitus. After generating periodograms for individual subject omics signals, we constructed within-person omics networks and analyzed personal-level immune changes. The results identified both individual-level responses to immune perturbation, and the clusters of individuals that have similar behaviors in immune response and which were associated to measures of their diabetic status.Entities:
Mesh:
Year: 2022 PMID: 35840765 PMCID: PMC9284494 DOI: 10.1038/s41598-022-16326-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Cohort description. Summary distributions across sexes for (a) Age, (b) observation window, and (c) visits for different conditions. (d) Proportion of time series from different data modalities.
Figure 2Workflow. Following the initial parsing of multiple omics datasets (i), our workflow has two main branches: (ii) single subject analysis and (iii) multi-subject similarity analysis, with examples of the output shown and relevant figures and tables.
Figure 3Single individuals’ multiomics clusters. Two examples of Lag 1 classification outcomes are shown for (a) Subject ZKFV71L and (b) Subject ZTMFN3O. In these examples the information is summarized as follows: Left panel: the cluster of groups/subgroups for Lag 1 class are shown in the visits time frame. The visit time points have been labeled by healthy status, where H: Healthy, W: Weight gain/loss, Im: Immunization, In: Infection. Middle panel: the community structure of visits within each subgroup, where the community structure is based on our visibility-graph-based community detection algorithm[24]. Right panel: corresponding autocorrelations for the time series shown.
Statistically significant (FDR < 0.05) Reactome pathways results for subject ZKFV71L and ZTMFN3O for autocorrelation Lag 1.
| Reactome pathway | Matched IDs | FDR | |
|---|---|---|---|
| Endosomal/Vacuolar pathway | 14 | 1.10E−13 | 3.05E−11 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 15 | 1.17E−13 | 3.05E−11 |
| Interferon alpha/beta signaling | 16 | 4.90E−11 | 8.48E−09 |
| ER-Phagosome pathway | 14 | 1.82E−09 | 2.37E−07 |
| Interferon gamma signaling | 16 | 3.32E−09 | 3.45E−07 |
| Antigen processing-Cross presentation | 14 | 8.14E−09 | 7.00E−07 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 15 | 4.82E−07 | 3.56E−05 |
| Interferon Signaling | 16 | 1.49E−06 | 9.71E−05 |
| Class I MHC mediated antigen processing and presentation | 17 | 3.52E−06 | 0.000200 |
| Adaptive Immune System | 23 | 9.36E−05 | 0.00487 |
| RUNX3 regulates RUNX1-mediated transcription | 2 | 0.000718 | 0.0337 |
| Attenuation phase | 7 | 2.415E−10 | 5.121E−08 |
| HSF1-dependent transactivation | 7 | 1.152E−09 | 1.221E−07 |
| Regulation of HSF1-mediated heat shock response | 7 | 9.528E−08 | 6.670E−06 |
| Cellular response to heat stress | 7 | 3.135E−07 | 1.462E−05 |
| HSF1 activation | 5 | 3.482E−07 | 1.462E−05 |
| Cellular responses to stress | 12 | 4.469E−05 | 0.002 |
| Cellular responses to stimuli | 12 | 5.365E−05 | 0.002 |
| RMTs methylate histone arginines | 3 | 7.407E−04 | 0.019 |
| Interleukin-10 signaling | 7 | 2.416E−07 | 8.408E−05 |
| Signaling by Interleukins | 13 | 1.283E−05 | 0.0022 |
| NR1H3 and NR1H2 regulate gene expression linked to cholesterol transport and efflux | 4 | 0.00032 | 0.0353 |
| Signaling by Nuclear Receptors | 8 | 0.00057 | 0.0353 |
| Cytokine Signaling in Immune system | 14 | 0.00073 | 0.0353 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | 2 | 0.00073 | 0.0353 |
| Inhibition of Signaling by Overexpressed EGFR | 2 | 0.00073 | 0.0353 |
| NR1H2 and NR1H3-mediated signaling | 4 | 0.00083 | 0.0353 |
| NR1H2 and NR1H3 regulate gene expression to limit cholesterol uptake | 2 | 0.00114 | 0.0353 |
| NR1H2 and NR1H3 regulate gene expression linked to gluconeogenesis | 2 | 0.00114 | 0.0353 |
| NR1H2 and NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | 2 | 0.00114 | 0.0353 |
| EGFR interacts with phospholipase C-gamma | 2 | 0.00137 | 0.0357 |
| Interleukin-18 signaling | 2 | 0.00137 | 0.0357 |
Frequency of signals with statistically significant temporal trends in individuals.
| ID | Source | # Occurrences |
|---|---|---|
| genus_Streptococcus | Nares | 43 |
| IP10 | Cytokine | 43 |
| class_Gammaproteobacteria | Nares | 42 |
| family_Streptococcaceae | Nares | 39 |
| phylum_Proteobacteria | Gut | 38 |
| IL13 | Cytokine | 38 |
| PDGFBB | Cytokine | 37 |
| class_Bacilli | Gut | 35 |
| family_Streptococcaceae | Gut | 35 |
| genus_Streptococcus | Gut | 35 |
| order_Lactobacillales | Gut | 34 |
| class_Betaproteobacteria | Nares | 34 |
| genus_Dorea | Gut | 33 |
| TGFA | Cytokine | 33 |
| IL27 | Cytokine | 33 |
| TGFB | Cytokine | 33 |
| phylum_Bacteroidetes | Nares | 33 |
| genus_Blautia | Gut | 33 |
| ALKP | Clinical | 32 |
| family_Micrococcaceae | Nares | 32 |
| MCP1 | Cytokine | 32 |
| genus_Flavonifractor | Gut | 32 |
| class_Bacteroidia | Nares | 32 |
| order_Bacteroidales | Nares | 32 |
| family_Propionibacteriaceae | Nares | 32 |
| genus_Propionibacterium | Nares | 32 |
| genus_Clostridium.XlVa | Gut | 32 |
| GCSF | Cytokine | 31 |
| MIG | Cytokine | 31 |
| genus_Oscillibacter | Gut | 31 |
| IL22 | Cytokine | 31 |
| genus_Clostridium.IV | Gut | 31 |
| CD40L | Cytokine | 30 |
| VEGF | Cytokine | 30 |
| order_Lactobacillales | Nares | 30 |
| SCF | Cytokine | 30 |
| EGF | Cytokine | 30 |
| family_Coriobacteriaceae | Gut | 30 |
| order_Coriobacteriales | Gut | 30 |
Mann–Whitney U test for different measures between two different communities.
| Comparison | BMI | SSPG | Matsuda Index | Disposition Index | isrMax |
|---|---|---|---|---|---|
| C0 vs C1 Female | 0.79 | 0.95 | 0.62 | 0.87 | 0.87 |
| C0 vs C1 Male | 0.60 | 0.91 | 0.76 | 0.90 | 0.27 |
| C0 vs C1 Total | 0.26 | 0.82 | 0.50 | 0.27 | 0.61 |
| C0 vs C2 Female | 0.09 | 0.90 | 0.70 | 0.97 | 0.77 |
| C0 vs C2 Male | 0.97 | 0.32 | 0.77 | 0.77 | 0.95 |
| C0 vs C2 Total | 0.19 | 0.57 | 0.53 | 0.97 | 0.91 |
| C0 vs C3 Female | 0.43 | 0.14 | 0.14 | ||
| C0 vs C3 Male | 0.91 | 0.95 | 0.64 | 1.00 | |
| C0 vs C3 Total | 0.68 | 0.053 | |||
| C1 vs C2 Female | 0.39 | 0.83 | 0.26 | 1.00 | 0.91 |
| C1 vs C2 Male | 0.71 | 0.58 | 0.52 | 0.52 | 0.52 |
| C1 vs C2 Total | 0.086 | 0.67 | 0.17 | 0.23 | 0.56 |
| C1 vs C3 Female | 0.43 | 0.10 | 0.80 | 0.40 | 0.40 |
| C1 vs C3 Male | 1.00 | 0.68 | 0.93 | 0.15 | |
| C1 vs C3 Total | 0.083 | 1.00 | 0.16 | ||
| C2 vs C3 Female | 0.29 | 0.29 | 0.29 | ||
| C2 vs C3 Male | 0.052 | 0.57 | 1.00 | 0.29 | 1.00 |
| C2 vs C3 Total | 0.51 | 0.15 |
The labels C0, C1, C2,C3 correspond to Community 0, Community 1 Community 2 and Community 3, respectively. Statistically significant (p value < 0.05) results are shown in italics.
Figure 4Similarity analysis across individuals. (a) The k-means based community structure of the subjects’ similarity network (nodes represent subjects and weighted edges omics showing similar temporal behavior across individuals). (b)–(f) Distributions of five types of measures in the 4 network communities by gender: (b) BMI; (c) DI, disposition index; (d) SSPG, steady-state plasma glucose; (e) Matsuda index and (f) isrMax, maximum insulin secretion rate.
Statistically significant (FDR < 0.05) Reactome pathways results of top quartile highest genes for Communities 0 and 2.
| Reactome pathway | Matched IDs | FDR | |
|---|---|---|---|
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 35 | 1.11E−16 | 3.77E−15 |
| Endosomal/Vacuolar pathway | 35 | 1.11E−16 | 3.77E−15 |
| Class I MHC mediated antigen processing and presentation | 35 | 1.11E−16 | 3.77E−15 |
| ER-Phagosome pathway | 35 | 1.11E−16 | 3.77E−15 |
| Antigen processing-Cross presentation | 35 | 1.11E−16 | 3.77E−15 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 36 | 1.11E−16 | 3.77E−15 |
| Interferon gamma signaling | 36 | 1.11E−16 | 3.77E−15 |
| Interferon alpha/beta signaling | 36 | 1.11E−16 | 3.77E−15 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | 35 | 1.11E−16 | 3.77E−15 |
| Interferon Signaling | 36 | 1.11E−16 | 3.77E−15 |
| SARS-CoV-2-host interactions | 35 | 1.11E−16 | 3.77E−15 |
| SARS-CoV-2 Infection | 35 | 1.11E−16 | 3.77E−15 |
| SARS-CoV Infections | 35 | 1.11E−16 | 3.77E−15 |
| Cytokine Signaling in Immune system | 39 | 1.54E−11 | 4.94E−10 |
| Adaptive Immune System | 37 | 2.03E−11 | 6.10E−10 |
| Infectious disease | 35 | 1.63E−05 | 4.56E−4 |
| TRKA activation by NGF | 2 | 1.49E−4 | 0.0400 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 4 | 4.98E−4 | 0.0400 |
| Activation of TRKA receptors | 2 | 5.88E−4 | 0.0400 |
| Ca2+ activated K+ channels | 2 | 5.88E−4 | 0.0400 |